期刊文献+

抗菌药物整治与病原菌耐药趋势变化相关性分析 被引量:5

Analysis on correlation between antibiotic regulation with drug resistance trend change of pathogenic bacteria
下载PDF
导出
摘要 目的连续监测并分析医院实行抗菌药物干预政策后临床分离病原菌耐药性变化,评估抗菌药物干预与病原菌耐药性相关性。方法选取近3年实行抗菌药物干预的第三、四代头孢菌素,连续3年动态监测肠杆菌科病原菌对其耐药性的变化,设干预组和对照组。结果干预前后产ESBLs菌株检出率有显著性下降(P<0.05);病原菌对干预使用的第三、四代头孢菌素耐药性降低,干预前后差异有统计学意义(P<0.05);而病原菌对对照1组抗菌药物哌拉西林/他唑巴坦和阿莫西林/棒酸耐药性无显著增加,对对照2组抗菌药物耐药性影响不大。结论长期合理对抗菌药物进行综合干预有益于延缓病原菌耐药性。 Objective To continuously monitor and analyze the drug resistance change of clinically isolated pathogenic bacteria after implementing the hospital antibiotic interventional policy and to evaluate the correlation between the antibiotic intervention and drug resistance of pathogenic bacteria.Methods Third-generation and fourth generation cephalosporins implementing the antibiotic intervention for recent 3years were selected and the change of resistance of Enterobacteriaceae pathogenic bacteria to them were continuously monitored for 3successive years.The intervention group and the control group were set up.Results The detection rate of ESBLs producing strains were significantly decreased after intervention(P〈0.05);and the resistance rates of pathogens to used third-generation and fourth generation cephalosporins were reduced with statistically significant difference between before and after intervention(P〈0.05);the resistance of pathogenic bacteria to piperacillin/tazobactam and amoxicillin/clavulanic acid in the control group 1had no significant increase,the resistance to antibiotics in the control group 2had little influence.Conclusion The long-term and rational comprehensive intervention to antibiotics is beneficial to delay the drug resistance of pathogenic bacteria.
出处 《国际检验医学杂志》 CAS 2016年第1期31-32,共2页 International Journal of Laboratory Medicine
关键词 细菌耐药性 抗菌药物干预 动态监测 bacterial drug resistance antibiotic intervention dynamic surveillance
  • 相关文献

参考文献8

  • 1Roehr B. Renewed effort are needed to curb antibiotic resistance [J]. BMJ,2012,345(15),7778. 被引量:1
  • 2Hvistendahl M. Public heath. China takes aim at rampant antibiot- ic resistance[J]. Science, 2012,336(7) : 795. 被引量:1
  • 3CLSI Clinical and Laboratory Standards Institute. M100-S24 Per- formance standards for antimicrobial susceptibility testing.-24rd informational supplement[S. Wayne: CLSI, 2014. 被引量:1
  • 4Gerber JS,Prasad PA,Fiks AG et al. Durability of benefits of an out- patient antimicrobial stewardship intervention after discontinuation of audit and feedback[J]. JAMA,2014,312(23) 2569-2570. 被引量:1
  • 5Timothy H. Dellit, Infectious diseases society of america and the society for healthcare epidemiology of america guidelines for de veloping an institutional program to enhance antimicrobia[stew ardship[J]. Clinical Infectious Diseases, 2007,44(2) 159-177. 被引量:1
  • 6《抗菌药物临床应用管理办法》(卫生部84号令),2012. 被引量:1
  • 7Carlos Bantar, et a[, Replacement of Broad-Spectrum Cephalospo- rins by Piperacillin Tazobactam: Impact on Sustained High Rates of Bacterial Resistance[J]. Antimicrobial Agents and Chemothera- py,2004,48(2):392 395. 被引量:1
  • 8高娅文,杨宇,吴悦陶,曹玮,周琪伟.抗生素干预后ESBLs-KPN和ESBLs-ECO的变化[J].中南大学学报(医学版),2010,35(2):165-170. 被引量:7

二级参考文献13

  • 1裴保香,郭绍来,王睿,周筱青.大肠埃希菌耐药性与头孢菌素类用量变化的相关性分析[J].中华医院感染学杂志,2004,14(4):373-376. 被引量:35
  • 2刘兴态,汪华,曾蓉.产ESBLs肺炎克雷伯菌和大肠埃希菌的检测及耐药性分析[J].检验医学与临床,2007,4(3):182-183. 被引量:19
  • 3Perez F, Endimiani A, Hujer K M, et al. The continuing challenge of ESBLS [ J ]. Curr Opin Pharmacol, 2007, 7 (5) : 459 -469. 被引量:1
  • 4WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment [ M ]. 6th ed. Oslo, Norway: World Health Organization, 2003. 被引量:1
  • 5Slama T G, Amin A, Brunton S A, et al. Council for appropriate and rational antibiotic therapy (CARAT). A clini- cian' s guide to the appropriate and accurate use of antibiotics : the Council for Appropriate and Rational Antibiotic Therapy ( CARAT ) criteria [ J ] . Am J Med, 2005 , 118 (TA) :1S-6S. 被引量:1
  • 6McGowan JE Jr. Resistance in nonfermenting gram-negative bacteria : muhidrug resistance to the maximum [ J ] . Am J Infect Control, 2006,34 ( 5 suppl 1 ) : S29 -S37. 被引量:1
  • 7Bradford P A. Extended-spectrum beta-lactamases in the 21 st century : Characterization, epidemiology, and detection of this important resistance threat [ J ] . Clin Microbiol Rev, 2001,14(4) :933-951. 被引量:1
  • 8Endimiani A, Paterson D L. Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum Beta-lactamases [ J ]. Semin Respir Crit Care Med, 2007, 28(6) :646-655. 被引量:1
  • 9Paterson D L. Resistance in gram-negative bacteria: enterobacteriaceae[J]. Am 2 Med,2006,119(6 Suppl 1) :S20-S28. 被引量:1
  • 10Martinez J A, Agnilar J, Almela M, et al. Prior use of earbapenems may be a significant risk factor for extended-spectrum { beta } -lactamase producing Escherichia coli or Klebsiella spp. in patients with baeteraemia [ J ]. J Antimicrob Chemother, 2006, 58(5) :1082-1085. 被引量:1

共引文献6

同被引文献45

引证文献5

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部